The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials
D. G. Bostwick, H. B. Burke, T. M. Wheeler, L. W.K. Chung, R. Bookstein, T. G. Pretlow, R. B. Nagle, R. Montironi, M. M. Lieber, R. W. Veltri, W. E. Grizzle, D. J. Grignon
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials'. Together they form a unique fingerprint.